Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 93, Issue , 2015, Pages 27-36

  Zhao, Xiaojing ^a   Chen, Qi ^b   Li, Yusang ^a,b   Tang, Hebin ^b   Liu, Wei ^a   Yang, Xiangliang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES   (China)

Author keywords

Co delivery lipid nanoparticles; Curcumin; Doxorubicin; Hepatocellular carcinoma; Multidrug resistance; Synergistic effect; Tumor growth inhibition

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CURCUMIN; CYCLINE; DIETHYLNITROSAMINE; DOXORUBICIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPID NANOPARTICLE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; NANOPARTICLE; PROTEIN BAK; PROTEIN BCL 2; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DELAYED RELEASE FORMULATION; DRUG CARRIER; DRUG COMBINATION; LIPID; TUMOR MARKER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CELL INFILTRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; FATTY LIVER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INFLAMMATORY CELL; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER INJURY; LIVER TOXICITY; LIVER WEIGHT; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; SUSTAINED DRUG RELEASE; TUMOR GROWTH; ZETA POTENTIAL; ANIMAL; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; CHEMISTRY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS, EXPERIMENTAL; MEDICINAL CHEMISTRY; METABOLISM; NANOMEDICINE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHARMACEUTICS; PROCEDURES; SOLUBILITY; TIME; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DELAYED-ACTION PREPARATIONS; DIETHYLNITROSAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPIDS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; NANOMEDICINE; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; PARTICLE SIZE; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 84926212392     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.03.003     Document Type: Article

References (41)

1. A. Villanueva, and J.M. Llovet Targeted therapies for hepatocellular carcinoma Gastroenterology 140 2011 1410 1426
2. U. Asghar, and T. Meyer Are there opportunities for chemotherapy in the treatment of hepatocellular cancer J. Hepatol. 56 2012 686 695
3. Y.D. Livney, and Y.G. Assaraf Rationally designed nanovehicles to overcome cancer chemoresistance Adv. Drug Delivery Rev. 65 2013 1716 1730
4. A.K. Iyer, A. Singh, S. Ganta, and M.M. Amiji Role of integrated cancer nanomedicine in overcoming drug resistance Adv. Drug Delivery Rev. 65 2013 1784 1802
5. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
6. A.M. Chen, M. Zhang, D. Wei, D. Stueber, O. Taratula, and T. Minko et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells Small 5 2009 2673 2677
7. D.Y. Kim, M.J. Kim, H.B. Kim, J.W. Lee, J.H. Bae, and D.W. Kim et al. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc Biochim. Biophys. Acta 2011 1812 796 805
8. K.M. Comerford, T.J. Wallace, J. Karhausen, N.A. Louis, M.C. Montalto, and S.P. Colgan Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene Cancer Res. 62 2002 3387 3394
9. M. Saraswathy, and S. Gong Different strategies to overcome multidrug resistance in cancer Biotechnol. Adv. 31 2013 1397 1407
10. M.E. Davis, Z.G. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug. Discovery 7 2008 771 782
11. C.M. Hu, S. Aryal, and L.F. Zhang Nanoparticle-assisted combination therapies for effective cancer treatment Ther. Delivery 1 2010 323 334
12. X. Fan, C. Zhang, D.B. Liu, J. Yan, and H.P. Liang The clinical applications of curcumin: current state and the future Curr. Pharm. Des. 19 2013 2011 2031
13. S.E. Chuang, M.L. Kuo, C.H. Hsu, C.R. Chen, J.K. Lin, and G.M. Lai et al. Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis Carcinogenesis 21 2000 331 335
14. S. Ganta, and M. Amiji Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells Mol. Pharm. 6 2009 928 939
15. H. Choi, Y.S. Chun, S.W. Kim, M.S. Kim, and J.W. Park Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition Mol. Pharmacol. 70 2006 1664 1671
16. M.X. Xu, L. Zhao, C. Deng, L. Yang, Y. Wang, and T. Guo et al. Curcumin suppresses proliferation and induces apoptosis of human hepatocellular carcinoma cells via the wnt signaling pathway Int. J. Oncol. 43 2013 1951 1959
17. R.A. Sharma, A.J. Gescher, and W.P. Steward Curcumin: the story so far Eur. J. Cancer 41 2005 1955 1968
18. K. Deepa, S. Singha, and T. Panda Doxorubicin nanoconjugates J. Nanosci. Nanotechnol. 14 2014 892 904
19. S. Barui, S. Saha, G. Mondal, S. Haseena, and A. Chaudhuri Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature Biomaterials 35 2014 1643 1656
20. R. Misra, and S.K. Sahoo Coformulation of doxorubicin and curcumin in poly(d,l-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells Mol. Pharm. 8 2011 852 866
21. B.L. Wang, Y.M. Shen, Q.W. Zhang, Y.L. Li, M. Luo, and Z. Liu et al. Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer Int. J. Nanomed. 8 2013 3521 3531
22. J. Duan, H.M. Mansour, Y. Zhang, X. Deng, Y. Chen, and J. Wang et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles Int. J. Pharm. 426 2012 193 201
23. H. Qian, Y. Yang, and X. Wang Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy Eur. J. Pharm. Sci. 43 2011 125 131
24. X. Zhao, Q. Chen, W. Liu, Y. Li, H. Tang, and X. Liu et al. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer Int. J. Nanomed. 10 2015 257 270
25. C. Zhang, F. Peng, W. Liu, J. Wan, C. Wan, and H. Xu et al. Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats Int. J. Nanomed. 9 2014 1049 1063
26. P. Merle, M. Chevallier, R. Levy, M. Maisonnas, O. Terradillos, and S.N. Ahmed et al. Preliminary results of interferon-a therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice J. Hepatol. 34 2001 562 569
27. L.X. Shi, R. Ma, R. Lu, Q. Xu, Z.F. Zhu, and L. Wang et al. Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU Cancer Lett. 269 2008 101 110
28. C. Puglia, G. Frasca, T. Musumeci, L. Rizza, G. Puglisi, and F. Bonina et al. Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice Eur. J. Pharm. Biopharm. 81 2012 288 293
29. R.R. Zhu, L.L. Qin, M. Wang, S.M. Wu, S.L. Wang, and R. Zhang et al. Preparation, characterization, and anti-tumor property of podophyllotoxin-loaded solid lipid nanoparticles Nanotechnology 20 2009 055702
30. C.C. Chen, T.H. Tsai, Z.R. Huang, and J.Y. Fang Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics Eur. J. Pharm. Biopharm. 74 2010 474 482
31. D. Pramanik, N.R. Campbell, S. Das, S. Gupta, V. Chenna, and S. Bisht et al. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy Oncotarget 3 2012 640 650
32. L. Barraud, P. Merle, E. Soma, L. Lefrancois, S. Guerret, and M. Chevallier et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo J. Hepatol. 42 2005 736 743
33. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
34. X. Wang, H. Bai, X. Zhang, J. Liu, P. Cao, and N. Liao et al. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis Carcinogenesis 34 2013 1323 1330
35. B.K. Yoo, D. Chen, Z.Z. Su, R. Gredler, J. Yoo, and K. Shah et al. Molecular mechanism of chemoresistance by astrocyte elevated gene-1 Cancer Res. 70 2010 3249 3258
36. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug. Discovery 5 2006 219 234
37. N. Romiti, R. Tongiani, F. Cervelli, and E. Chieli Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes Life Sci. 62 1998 2349 2358
38. B.S. Vinod, T.T. Maliekal, and R.J. Anto Phytochemicals as chemosensitizers: from molecular mechanism to clinical significance Antioxid. Redox Signal. 18 2013 1307 1348
39. L.L. Yu, J.G. Wu, N. Dai, H.G. Yu, and J.M. Si Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-kappaB transcription factor Oncol. Rep. 26 2011 1197 1203
40. L. Milane, S. Ganesh, S. Shah, Z.F. Duan, and M. Amiji Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology J. Controlled Release 155 2011 237 247
41. J. Wang, Y. Ma, H. Jiang, H. Zhu, L. Liu, and B. Sun et al. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice J. Hepatol. 55 2011 359 368